James Chih-Hsin Yang

James Chih-Hsin Yang is a pioneering thoracic oncologist who has led definitive trials of second-generation EGFR inhibitors afatinib and dacomitinib in NSCLC. His work on the LUX-Lung trial series established afatinib's efficacy and safety profile across different EGFR mutation types. He has extensively studied EGFR mutation prevalence and outcomes in Asian populations where EGFR-driven NSCLC is particularly common. His laboratory investigates adaptive resistance mechanisms in EGFR-mutant lung cancer.